Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25437508 | 0.87 | COMT (0.55) | COMTKDM4EFTOCNR1 | |
| SCHEMBL17962295 | 0.84 | COMT (0.65) | COMTKDM4EFTOPOLBDTYMK | |
| SCHEMBL31399749 | 0.80 | CHRM1 (0.49) | CNR1POLBSMARCA2SMARCA4PBRM1 | |
| SCHEMBL30439348 | 0.77 | CNR1 (0.44) | CNR1SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL24177978 | 0.77 | CNR1 (0.44) | CNR1SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL23795306 | 0.77 | CNR1 (0.44) | CNR1SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL17960010 | 0.77 | COMT (0.67) | COMTKDM4EFTO | |
| SCHEMBL17962392 | 0.77 | COMT (0.67) | COMTKDM4EFTO | |
| SCHEMBL17960029 | 0.77 | COMT (0.67) | COMTKDM4EFTO | |
| SCHEMBL31399755 | 0.76 | CNR1 (0.43) | CNR1DTYMKGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | claimed |
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | claimed |
| US-20180305360-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2018-10-25 | — | — | US | claimed |
| US-10035799-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2018-07-31 | — | — | US | claimed |
| EP-3250209-A1 | COMT INHIBITING METHODS AND COMPOSITIONS | Lieber Institute For Brain Development (US) | 2017-12-06 | — | — | EP | claimed |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2016-08-04 | — | — | US | claimed |
| WO-2016123576-A1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2016-08-04 | — | — | WO | claimed |
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180305360-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2018-10-25 | — | — | US | disclosed |
| US-10035799-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2018-07-31 | — | — | US | disclosed |
| EP-3250209-A1 | COMT INHIBITING METHODS AND COMPOSITIONS | Lieber Institute For Brain Development (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016123576-A1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035799-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | COMT 1/4885KDM4E 1957/4885FTO 130/4885 |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | COMT 1/4885KDM4E 1957/4885FTO 130/4885 |
| US-20180305360-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | COMT 1/4885KDM4E 1957/4885FTO 130/4885 |
| US-10479790-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | COMT 1/4885KDM4E 1957/4885FTO 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.